EUCTR2019-002245-37-NL进行中（未招募）1 期
A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Subjects to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 mg when Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Coadministrationof the Separate Agents (Darunavir, Cobicistat, and Emtricitabine/Tenofovir Alafenamide), Under Fed Conditions
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subject:
- •1. Must be a man or woman between 18 and 55 years of age, extremes included, at screening.
- •2. Must have a body mass index (BMI; weight [kg]/height2 [m]2) between 18.5 and 30.0 kg/m2 (extremes included), and a body weight of not less than 50 kg at screening.
- •3. Must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study, before any study-related procedures take place.
- •4. Must be healthy on the basis of physical examination, medical history, vital signs, and ECG performed at screening (results must be available on Day -1). If there are abnormalities (other than those listed in inclusion criterion 10 [for blood pressure]), the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator.
- •5. Must be healthy on the basis of clinical laboratory test performed at screening (results must be available on Day -1). If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges (other than those listed in exclusion criterion 2), the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant. This determination must be recorded in the subject's source documents and initialed by the investigator.
- •6. A woman (of childbearing potential) must have a negative highly sensitive serum betahuman chorionic gonadotropin pregnancy test, 4 days or less before dosing of the first treatment period.
- •7. Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for subject participating in clinical studies.
- •Before randomization, a female subject must be either:
- •a. Not of childbearing potential defined as:
- •- premenarchal
- •A premenarchal state is one in which menarche has not yet occurred
- •- postmenopausal
- •A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level (>33.4 IU/L or mIU/mL in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy, however in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient. If there is a question about menopausal status in women on hormone
- •replacement therapy (HRT), the woman will be required to use one of the non-estrogen-containing hormonal highly effective contraceptive methods if she wishes to continue HRT during the study.
- •- permanently sterile
- •Permanent sterilization methods include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and
- •bilateral oophorectomy.
- •b. Of childbearing potential and
- •- be not heterosexually active, or have a vasectomized partner for the duration of the study and for at least 90 days after receiving the last dose of study drug OR
- •- practicing a highly effective method of birth control (as specified below) before entry and agree to continue to use a highly effective method of contraception throughout the study, and for at least 90 days after receiving the last dose of study drug. Women with tubal ligation are required to use one additional contraceptive method.
- •Note: Estrogenbased
排除标准
- •1. History or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease (including bronchospastic respiratory disease), diabetes mellitus, hepatic or renal insufficiency (eg, estimated creatinine clearance below <90 mL/min at screening), gastrointestinal disease (such as significant diarrhea, gastric stasis, or constipation that in the investigator’s opinion could influence drug absorption or bioavailability), thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the
- •subject or that could interfere with the interpretation of the study results.
- •2. One or more of laboratory abnormalities at screening as defined by the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events and in accordance with the normal ranges of the clinical laboratory.
- •3. Clinically significant abnormalities during physical examination, vital signs, or 12-lead electrocardiogram (ECG) at screening or at admission to the study center as deemed appropriate by the investigator.
- •4. History of clinically significant skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, food allergy, or urticaria.
- •5. Has taken any disallowed therapies as noted in Section 5.5 of the protocol before the planned first intake of study drug.
- •6. History of drug or alcohol abuse according to Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria within 1 year before screening or positive test result(s) for alcohol and/or drugs of abuse either at screening or on Day -1 of each treatment period.
- •7. A history of clinically significant drug allergy such as, but not limited to, sulfonamides and penicillins, or drug allergy diagnosed in previous studies with experimental drugs.
- •8. Known allergies, hypersensitivity, or intolerance to DRV, COBI, FTC, and/or TAF, or any of their excipients.
- •9. Known allergy to heparin or history of heparin induced thrombocytopenia.
- •10. Donation of blood or plasma within 2 months preceding the first intake of study drug or intention to donate blood or blood products during the study.
- •11. Has received an investigational drug or used an investigational medical device within 60 days before the first intake of study drug.
- •12. Woman who is pregnant, or breast-feeding, or planning to become pregnant during this study or within 90 days after the last intake of study drug, or a woman of childbearing potential who is unwilling to use acceptable methods of contraception.
- •13. Man who plans to father a child while enrolled in this study or within 90 days after the last intake of study drug, or who is unwilling to use acceptable methods of contraception.
- •14. A story of hepatitis A antibody immunoglobulin M (IgM), hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for hepatitis A antibody IgM, HBsAg or anti-HCV at screening.
- •15. A history of HIV-1 or HIV-2 infection, or tests positive for HIV-1 or HIV-2 at screening.
- •16. A history of smoking or use of nicotine-containing substances within 2 months prior to screening, as determined by medical history or subject’s verbal report. A urine cotinine test will be perfor
研究者
相似试验
已完成
不适用
A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Adult Participants to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 mg when Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate Agents (Darunavir, Cobicistat, and Emtricitabine/Tenofovir Alafenamide), Under Fed CoAIDSHIV10021460NL-OMON49227Janssen Sciences Ireland UC32
进行中（未招募）
1 期
A study into a combination treatment for HIV-1 in which the safety,absorption and elimination of a combination pill is compared to that of theindividual components.Healthy VolunteersHuman immunodeficiency virus type 1 (HIV-1)MedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2020-003396-18-NLJanssen Sciences Ireland UC32
招募中
不适用
A Single-Dose, Open-Label, Randomized, Replicate Crossover Pivotal Bioequivalence Study in Healthy Subjects to Assess the Bioequivalence of Darunavir 675 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg in the Presence of Cobicistat 150 mg when Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Coadministration of the Separate Agents (Darunavir, Cobicistat, and Emtricitabine/Tenofovir Alafenamide), Under Fed ConditionsAIDSHIV10021460NL-OMON49638Janssen Sciences Ireland UC32
已完成
不适用
A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of each drug, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male VolunteersEndocrine, nutritional and metabolic diseaseKCT0001173Dong-A ST64
Unknown
1 期
Comparative bioavailability Study and food-effect of Amlodipine 5 mg powder for oral solution in Healthy Thai VolunteersHealthy volunteerAmlodipine, Powder for oral solution, Comparative bioavailability study, Food effect study, Healthy Thai VolunteerTCTR20220908002International Bio Service Co., Ltd.30